
Muse bio appoints John Stuelpnagel chairman of board of directors
BOULDER -- Muse bio , a privately-held company leading the development of next-generation genome engineering capabilities, announced Dr. John Stuelpnagel , co-founder, first CEO and former COO... Read More
Tuesday May 16, 2017

Muse bio secures $23M Series B funding led by Venrock investor group
BOULDER -- Muse bio , a privately-held company leading the development of next-generation genome engineering capabilities, today announced completion of a$23 millionSeries B financing. The... Read More
Tuesday February 28, 2017